Objective: Critical limb ischemia (CLI) continues to place a significant encumbrance on patients and the health care system as it progresses to limb loss and long-term disability. Traditional methods of revascularization offer a significant benefit; however, for one-third of CLI patients, these surgical options are not technically possible or patency is severely limited by disease burden (deemed "poor-option" for revascularization). In a previous phase I trial, we demonstrated intramuscular injection of concentrated bone marrow aspirate (cBMA) via MarrowStim (Zimmer Biomet, Warsaw, Ind) harvest is safe and may decrease major amputation in patients with CLI unfit for surgical revascularization. Therefore, we describe and rationalize the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial, a study geared to provide the pivotal proof of efficacy of cBMA in CLI.
Critical limb ischemia (CLI) is a result of insufficient blood flow to maintain viability of the skin and muscles of the legs. 1 The clinical manifestations initially consist of rest pain, which progresses to tissue loss, an ominous sign. The incidence of CLI in the Western hemisphere is w220 new cases per 1 million per year, and 30% of these patients will not have options for surgical or endovascular revascularization. 2 For these "poor-option" patients, defined here as unsuitable for revascularization by one or more vascular surgeons, major amputation remains the only treatment for relief of symptoms. Consequently, 120 to 500 major amputations are performed each year per 1 million individuals, causing a severe economic burden. Rehabilitation in onefourth of these patients will fail, and they will require chronic institutional care or professional assistance at home. 3, 4 This effect on health care resources is tremendous because major amputation ranks as the sixth most expensive procedure in the United States, with a macroeconomic cost per annum estimated at $10.6 billion. 5 Beyond the physical disability and financial cost, there is a significant emotional toll as well. Psychologic testing of patients with CLI shows quality of life indices similar to patients with terminal malignancy. 6, 7 In response to this need for novel strategies to prevent amputations, there has been significant interest in the potential of cell-based therapies for promoting limb salvage in patients with CLI. In 2004, we initiated the first United States Food and Drug Administration-approved phase I/II trial in the United States, Somatic Cell Therapy for Critical Limb Ischemia, that demonstrated feasibility and safety of the intramuscular (IM) injection of autologous concentrated bone marrow aspirate (cBMA) in promoting amputation-free survival (AFS) in 29 patients (30 limbs) with CLI. 8 Multiple studies since then have shown that bone marrow-derived cells may have a therapeutic benefit in promoting limb salvage; however, these studies were small and lacked appropriate control populations. [9] [10] [11] [12] We attempt to fill this gap of knowledge with the phase III MOBILE trial (MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease).
CURRENT STATUS
MOBILE is a randomized, placebo-controlled, doubleblind phase III study evaluating the IM injection of cBMA containing autologous bone marrow mononuclear cells (ABMNCs) for the treatment of CLI patient with poor revascularization options. At this moment, enrollment, treatment, and follow-up are complete for all patients at the 52-week mark. Long-term follow-up (>1 year) is continuing. We are in the process of unblinding early results and beginning planned statistical analysis.
MOBILE TRIAL STUDY DESIGN
Randomization. After Institutional Review Board approval and patient consent, those who met inclusion criteria (Table I) were randomly assigned via computer assistance into treatment groups at a 3:1 ratio favoring cBMA administration into the ischemic limb. A (Fig 1) . Those enrolled in the placebo arm had the option to cross over to the treatment group after 52 weeks of follow-up, provided the sham-treated limb still met study inclusion and exclusion criteria. Patients who became eligible for revascularization because of clinical improvement during the treatment phase were not denied conventional revascularization in the form of angioplasty, stenting, or bypass.
Blinding. All patients were blinded to treatment because the procedure was conducted under general anesthesia. Unfortunately, blinding the treating physicians was not possible, but the evaluators of clinical efficacy (physicians, physician assistants, nurse practitioners, technicians, and nurses) were not aware of the patient treatment group. The unblinded treatment physicians evaluated the patients on postoperative day 1 for discharge purposes to minimize the ability of the blinded evaluators to deduce treatment group. Afterward, the unblinded treating physicians were not involved in patient care or follow-up. Specific treatment parameters that would give away the patient treatment group, such as marrow volume and marrow cell count, were kept in a file by the unblinded treating physicians, not accessible to blinded evaluators. Study-related communication between the unblinded and blinded personnel was minimized. If a decision for amputation was made, it was done by a blinded clinician not involved in the MOBILE trial.
Wound care. A comprehensive and multidisciplinary system of wound care was encouraged for all sites. Clinicians were given instructions to débride nonviable tissue, surrounding callus, and thick eschar if there was potential for healing. Podiatry-directed use of proper offloading shoes was used, depending on the wound location. Wounds were additionally dressed to maintain a proper moist environment, most often with hydrogels, gauze, or absorbent foam dressings. If wounds became infected, débridement and consideration for antibiotics, as appropriate, was encouraged. Treatment. The MarrowStim PAD Kit (Zimmer Biomet, Warsaw, Ind) is an investigational device and is not commercially available. MOBILE clinical data have not yet been evaluated by the Food and Drug Administration. Treatment is performed by aspiration of autologous bone marrow, concentration in the MarrowStim separator, and IM administration into the affected limb, all within a single procedure (Fig 2) . Thirty-six milliliters of treatment product are prepared from 360 mL of anticoagulated bone marrow aspirated bilaterally from the iliac crests. Three milliliters of cBMA are reserved for laboratory analysis, leaving 33 mL available for injection. cBMA is delivered via a small needle (22-23 gauge) in 0.75-mL aliquots 1.5 cm deep sequentially along the length of the lateral and medial lower leg (Fig 3) .
For the MOBILE trial, the MarrowStim procedure was performed under general anesthesia. Although the anesthesiologist could deviate from established protocols for patient safety, established study practice dictated induction of the patient with 0.3 mg/kg etomidate, followed by maintenance with 2% sevoflurane or 6% desflurane. Total anesthetic time ranged from 90 to 120 minutes. All patients stayed overnight for observation, and a blood count was obtained on postoperative day 1.
The sham procedure performed was designed to simulate the MarrowStim procedure described previously. As with cBMA harvest and injection, the patient was induced under general anesthesia. A skin puncture was made on both posterior iliac crests at the location where bone marrow is typically harvested. A large-bore needle was introduced to the periosteum; however, no penetration occurred. Centrifuges were run during the procedure to simulate background noise and homogenize treatment times so the recovery room staff could not deduce treatment groups. No IM injections were performed, but percutaneous needle punctures of the limb were performed sequentially in the same manner as in the MarrowStim group.
Follow-up. Patients who consented for inclusion into MOBILE were monitored for 52 weeks after their index intervention via a combination of clinic visits and telephone calls (Table II) . If the patient missed a visit, three additional attempts for contacts via telephone calls were performed, followed by certified mail. These patients were deemed high-risk for major amputation or death, and the inquiries were made to clarify the clinical condition. Long-term follow-up will consist of clinic visits at years 2 and 3 postprocedure, followed by telephone calls at years 4 and 5 (Table III) . All site investigators were responsible for participants receiving best medical therapy, as detailed by Berger and Hiatt. 13 Trial cessation rules were implemented for adverse events similar in nature to the previously described phase I/II safety trial. 8 Primary end points were death or major amputation (above the ankle) in the affected limb. Secondary end points relevant to the index limb in this protocol were incidence of minor amputation, incidence of gangrene,
The use of the (left) MarrowStim Separator and (center) Zimmer Biomet Biologics centrifuge (Warsaw, Ind) to (right) produce autologous concentrated bone marrow aspirate (cBMA). Left, Anticoagulated BMA (60 mL) is loaded into the separator through the center port and covered with the white cap. Center, The separator is placed into the centrifuge and spun at 3200 rpm for 15 minutes. During centrifugation, the marrow's nucleated cells collect between the two buoys within a fixed volume of fluid (6 mL). The red blood cells pack below the bottom buoy and the remaining plasma collects above the top buoy. Right, After centrifugation, the cBMA containing the nucleated cells is resuspended within the fixed volume of fluid. The cBMA is then recovered from the separator by connecting a syringe to the red capped port and extracting the contents.
wound healing, and pain scores. Major adverse limb events, including a major vascular intervention or procedure (eg, thrombectomy, thrombolysis, new bypass graft, jump/interposition graft revision) in the index limb, will be assessed at all long-term follow-up visits and phone calls. Other end points assessed were major adverse cardiovascular events, malignancy, and proliferative retinopathy. Participants were withdrawn from the study at any time by patient choice or treatment failure, and subsequent MOBILE follow-up was terminated.
DISCUSSION
Patients with CLI suffer a high rate of amputation, cardiovascular events (stroke, myocardial infarction), and death.
14 Although most patients have the option of surgical revascularization, those who are poor surgical candidates routinely progress to limb loss and decreased quality of life. 15 Available pharmacologic therapy in these patients with poor surgical options is limited. As such, clinicians have investigated other modalities for this population in need, such as prostanoid administration and spinal cord stimulation, with mixed results. 2 The concept of cell-mediated angiogenesis started from the observation that cluster of differentiation (CD) 34 þ cells isolated from peripheral blood had capacity to differentiate to fully functional endothelial cells. These cells, also found in bone marrow, were coined endothelial progenitor cells and coexpress CD34, CD133, and kinase insert domain receptor. [16] [17] [18] The utility of such a cell population was demonstrated in preclinical animal hind limb ischemia models before being trialed in patients with positive clinical results.
19-21
The utility of cBMA injections in humans was first described by Tateishi-Yuyama et al 21 Similar results were reported by other groups such as the TACT (Therapeutic Angiogenesis by Cell Transplantation) study. These investigators evaluated AFS after IM injection of ABMNCs in patients with Buerger and peripheral arterial disease (PAD) without revascularization options. The 3-year AFS were reported to be 91% and 60% respectively. 22 Previous cBMA products were obtained with simple Ficoll-assisted (GE Healthcare Inc, Princeton, NJ) separation. Last year, we published our results of simple Ficoll separation compared with MarrowStim isolation with the closed centrifugation system. The outputs of the MarrowStim PAD Kit and Ficoll separation were characterized using an automated hematology analyzer, colony-forming unit assays, and tubulogenesis assays. Hematology analysis indicated that the MarrowStim PAD Kit concentrated the total nucleated cells, mononuclear cells, and granulocytes compared with baseline BMA. Cells collected were positive for vascular endothelial growth factor 2, CD3, CD14, CD34, CD45, CD56, CD105, CD117, CD133, and Stro-1 antigen. Colony-forming unit assays demonstrated that the MarrowStim PAD Kit outputs a significantly greater number of mesenchymal stem cells and hematopoietic stem cells compared with cellular output by Ficoll separation. The difference in the number of endothelial progenitor cells by the two separation techniques was not significant. Isolated cells from both techniques formed interconnected nodes and microtubules in a three-dimensional cell culture assay. 23 
Fig 3.
Delivery pattern of the MarrowStim (Zimmer Biomet, Warsaw, Ind) product. Dosing of MarrowStim comprises of a one-time administration of autologous concentrated bone marrow aspirate (cBMA) immediately after bone marrow aspiration and MarrowStim separation. The cBMA is delivered intramuscularly via a 22-or 23-gauge needle, 1.5 cm deep, in 0.75-mL aliquots. Delivery is performed in 2-cm increments along the lateral and medial aspects of the lower leg to ensure even distribution. Initial delivery occurs along a single path on each side of the leg (black marks). Depending on the size of the leg and availability of cBMA, a second delivery path may have been used, offset 2 cm from the initial path (gray marks). Based on the location of ulcers, the location of pain, and the location of vessel occlusions (per pre-enrollment imaging, if available), cBMA delivery may have included but is not limited to the gastrocnemius, soleus, and tibialis anterior muscles, and the dorsum of the foot. Delivery sites were focused along the paths of the posterior tibial, anterior tibial, and dorsalis pedis arteries, beginning proximally and continuing distally.
In 2011, we reported our phase I/II trial investigating MarrowStim-assisted IM injections of ABMNCs in 29 poor-option CLI patients enrolled from 2005 to 2009. Although the study investigated the safety of IM MarrowStim cBMA injection, AFS was noted to be 86.3% at 1 year, with improvements in toe-brachial index, ankle-brachial index, rest pain, and first toe pressures. This compares favorably to reported baseline 1-year AFS rates of w60%. 24 Most importantly, the patients reported a 33%
increase in subjective quality of life measurements. We demonstrated an increased blood perfusion index using a novel positron emission tomography-computed tomography/H 2 O 15 imaging protocol corresponding to small vessel angiogenesis. In addition, there was a correlation between ankle-brachial index improvement and cells positive for kinase insert domain receptor in the treatment product. 8 This year, we reported 5-year follow-up of the same cohort, with 88% participation and continued AFS of 74%. 25 Interestingly, comparison of outcomes between bone marrow therapy and high-risk bypass surgery had similar rates of AFS at 1 year, as reported by the Dartmouth group in 2015. 26 Twenty patients receiving IM cBMA were compared with 35 patients undergoing infrainguinal bypass. The study did not include controls or blinded investigators. All patients were "poor-risk" patients, with 80% having rest pain or tissue loss. AFS was 78% for IM cBMA and 69% for high-risk bypass. 26 It is important to note this result meets the Society for Vascular Surgery's 1-year goal of AFS in CLI of 70%. 27 Unfortunately, previous trials have concentrated on clinical results, with little attention paid to the mechanism of action. However, the effect of ABMNCs has been hypothesized to be related to an upregulation of angiogenesis of the treated ischemic limb. 21, 28 This effect may be secondary to the elaboration of vascular endothelial growth factor, basic fibroblast growth factor, and angiopoietin-1 from the CD34 þ cBMA fraction. 29 In addition, angiopoietin-1 can be released from marrow hematopoietic cells to induce maturation of endothelial progenitor cells. 30 Nevertheless, the exact physiologic process has not been well elucidated thus far and would be crucial to the field, moving forward, to better define the effect of ABMNCs on ischemic limbs.
CONCLUSIONS
The MOBILE trial will be the largest completed prospective, randomized, placebo-controlled, double-blind trial investigating the efficacy of IM ABMNCs in CLI patients with poor options for surgical revascularization. If this phase III trial is successful in demonstrating increased AFS, bone marrow progenitors could prove to be a critically effective tool for patients with a historically poor outcome. 
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SUPPLEMENTARY STATISTICAL METHODS (online only).
Primary end point efficacy analysis. The primary efficacy end point for this prospective study was time to treatment failure. Treatment failed in those participants who had a major amputation or who died of cause. 8 The difference between treatment groups in this end point was estimated by the hazard ratio from a prespecified proportional hazards regression model. 31 Power estimation. The statistical power for the estimation of the hazard ratio was determined using wellknown methods 32 and by using empirical estimates of the hazard rates for the treatment and placebo groups.
Results from our phase I study showed that it was reasonable to assume the hazard rate for the investigational arm was constant for the 52-week portion of the study and therefore that amputation-free survival could be modeled using exponential distribution and so the event rates at 52 weeks could be used to calculate the hazard rate parameter. 33 The TransAtlantic Inter-Society Consensus working group published rates for the fate of the untreated patient with critical limb ischemia that might be used for the placebo group. 34 Their estimates were 35% for major amputation and 20% for death. For the purposes of power estimation, the most conservative estimation would be to use the 40% rate at 12 months for amputation and death combined.
To estimate a treatment group rate, a literature inspection 35 was initiated for studies in which some method of bone marrow harvest and preparation was used to improve some variety of peripheral arterial disease (PAD Imbalanced allocation and randomized stratification. Participants were randomly assigned with computer assistance to a treatment group using an unbalanced allocation ratio of 3:1 to maximize exposure to the investigational arm and minimize control participants to general anesthesia. 37 Diabetes mellitus comorbidity and baseline Rutherford severity score have been implicated as predictors of progression of disease. Therefore, the randomization was stratified by these factors. This had the advantage of providing exceptional balance between treatment groups 38 and creating four statistically independent strata. Data Safety and Monitoring Board. Because of the seriousness and nonreversibility of the combined study outcomes, an independent Data and Safety Monitoring Board was convened. 39 The principal objectives of the Data and Safety Monitoring Board were to monitor at 3-month intervals the overall blinded safety outcomes of the study and assess that these outcomes were within the prespecified stopping rules. The safety stopping rules were based on the blinded, overall (treatment group combined) total number of events. In addition, to protect study participants by assuring adequate statistical power remains to assess the primary objective of the study, a futility evaluation was scheduled to be performed for this study lock when 50% have been observed for at least 1 year. Conditional power was to be calculated under three assumptionsdnull hypothesis, alternative hypothesis, and current trenddand a futility criterion parameter provided as a guideline for deliberations during the evaluation of futility. 40 As a result of the nonuniform enrollment rate, however, the plan to conduct a futility evaluation was vacated.
Model specification for the proportional hazards regression. The primary analysis tested for the difference between treatment groups in the time to treatment failure at or before the 52-week follow-up visit, using a proportional hazards regression. 41 The use of allcause mortality avoids the complicated issue of competing risks. 42 The data will be modeled using a proportional hazards regression with treatment group as the independent variable adjusting for investigative site, diabetes status, and Rutherford class. The proportional hazards assumption will be assessed graphically. 41 If the observed data favor the MarrowStim group and we reject the null hypothesis, we can conclude that the time to treatment failures reported by participants at or before the 52-week follow-up visit in the MarrowStim group are longer than those reported by participants in the placebo group. In addition, time to the individual components, major amputation and mortality, will be evaluated separately using proportional hazards regression. The analysis will be conducted in an intention-totreat fashion. 43 Model specification for the mixed-model random missingness. Continuous secondary efficacy measures and vital signs will be analyzed by a repeated measures model, where the model contains fixed categoric effects of treatment, site, week, treatment-by-week, and fixed continuous effects of baseline, where subject is used in the repeated statement. 44 The baseline value of the variable being analyzed will be used as a covariate and will remain in the model, regardless of significance. The within-subject errors will be modeled using the unstructured covariance matrix, if the procedure converges. 45 If it does not, three other covariance structures, namely, compound symmetry, first order autoregressive, and heterogeneous first order autoregressive, will be investigated, and the structure giving the minimum value of the Akaike information criterion 46 will be selected in the final analysis. If the minimum Akaike information criterion is similar for all three structures, the compound symmetry structure will be selected.
